Please login to the form below

Not currently logged in
Email:
Password:

PharmaMar

This page shows the latest PharmaMar news and features for those working in and with pharma, biotech and healthcare.

NICE recommends two drugs for ovarian cancer but rejects three

NICE recommends two drugs for ovarian cancer but rejects three

But the cost-effectiveness body rejected GlaxoSmithKline's Hycamtin (topotecan), PharmaMar's Yondelis (trabectedin) and Lilly's Gemzar (gemcitabine) for treating the first recurrence of platinum-sensitive ovarian cancer.

Latest news

  • FDA approves Janssen’s Yondelis FDA approves Janssen’s Yondelis

    Luis Mora, managing director of Janssen's licensing partner PharmaMar, said: “Since Yondelis was first approved in Europe in 2007 approximately 50, 000 patients in 80 countries have benefited from this

  • PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma

    Cancer drug could be approved in the US within months. PharmaMar's cancer drug Yondelis could be approved in the US within a few months after it was fast-tracked by ... would be "financially transformative" for PharmaMar's parent company Zeltia.

  • NICE rejection of three ovarian cancer drugs stands

    NICE has over the past three years rejected three medicines for the disease: Lilly's Gemzar (gemcitabine), GlaxoSmithKline's Hycamtin (topotecan), both of which are also available as generics, and

  • NICE to update ovarian cancer drug guidelines NICE to update ovarian cancer drug guidelines

    However, NICE declined to recommend PharmaMar's Yondelis (trabectedin), as well as the generics gemcitabine and topetecan, as treatments for ovarian cancer that has returned for the first time six months ... The news is less positive for PharmaMar, which

  • Promising new agents for multiple myeloma Promising new agents for multiple myeloma

    Other anti-cancer agents. Plitidepsin (Aplidin; PharmaMar) induces cell death through various cellular pathways. ... PharmaMar received approval from the Independent Data Monitoring Committee (IDMC) in December 2012 to progress the trial to stage II,

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Bedrock hires new client services director Bedrock hires new client services director

    Patricia has combined her scientific and commercial understanding to work strategically with both large and small clients, including most recently Novartis, Abbott, Astellas, Bristol-Myers Squibb, PharmaMar and Roche, and we

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics